University of Hawai‘i at Manoa Homepage

Faculty

Charles Joel Rosser, MD, MBA, FACS

Charles Joel Rosser, MD, MBA, FACS

Degrees

  • MD
    UMDNJ-Robert Wood Johnson Medical School (Rutgers Medical School) Piscataway, New Jersey
  • MBA
    University of Phoenix Jacksonville, Florida

Research Focus

Dr. Rosser is an accomplished surgeon-scientist-entrepreneur with the sole focus of eliminating human cancers. In 2014, he joined the University of Hawaii Cancer Center as Program Director of the Clinical and Translational Research Program. From 2003-2009, he was at the University of Florida, where he developed the Genito-Urinary Oncology Program, an outpatient multidisciplinary program geared to provide accessible, high quality oncology care. From 2009-2013, Dr. Rosser served Chief of Urologic Oncology at the MD Anderson Cancer Center Orlando, where he developed a thriving clinical practice geared towards the management of non-muscle invasive bladder cancer, low-risk prostate cancer on active surveillance, and treatment of radiation recurrent prostate cancer.

During this time, Dr. Rosser has authored over 130 peer-reviewed publications and serves as Section Editor for BMC Cancer and BMC Urology. Dr. Rosser's previous extramural funding as principal investigator included awards from the Department of Defense, American Cancer Society, and a Team Science Award from the Department of Health (Florida).

Dr. Rosser's laboratory is dedicated to molecular diagnostics and novel therapeutics. Novel findings from his laboratory have been patented, which then have served as the nidus for the biotech start-up company, Nonagen BioScience Corporation (NBC), in which Dr. Rosser serves as president. NBC is partially funded by an NCI SBIR phase I/II grant. Lastly, Dr. Rosser has served as principal investigator of phase I-IV clinical trials (investigator-initiated, cooperative group, and pharmaceutical).

Publications

  • Miyake M, Goodison S, Lawton A, Gomes-Giacoia E, Rosser CJ. Angiogenin promotes tumoral growth and angiogenesis by regulating MMP2 expression via the ERK1/2 pathway. Oncogene, In press
  • Gomes-Giacoia E, Miyake M, Goodison S, Rosser CJ. (2013). Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther, Dec;12(12):2697-708.
  • Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ. (2013). Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J Hematol Oncol, Sep 3;6:65.
  • Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, Rosser CJ. (2013). Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Invest, Jul;93(7):768-78.
  • Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. (2012). A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev, Dec;21(12):2149-58.

Publication list via PubMed

Active Grants

  • C. Rosser, Academic PI, Goodison, Business PI
    1R44CA173921-01, Small Business Innovation Research
    NIH/NCI
    "Detection of molecular assays for non-invasive bladder cancer detection"
    $1,400,000
    The project is geared to refine our bladder cancer diagnostic signature in hopes of commercialization in the near future.
    9/1/2013-8/30/2015
Joomla16 Appliance - Powered by TurnKey Linux